Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 81

1.

Effect of natural polyphenols (Pycnogenol) on oxidative stress markers in children suffering from Crohn's disease--a pilot study.

Koláček M, Muchová J, Dvořáková M, Paduchová Z, Žitňanová I, Čierna I, Országhová Z, Székyová D, Jajcaiová-Zedníčková N, Kovács L, Ďuračková Z.

Free Radic Res. 2013 Aug;47(8):624-34. doi: 10.3109/10715762.2013.807508.

PMID:
23710677
2.

Role of fecal calprotectin testing to predict relapse in teenagers with inflammatory bowel disease who report full disease control.

van Rheenen PF.

Inflamm Bowel Dis. 2012 Nov;18(11):2018-25. doi: 10.1002/ibd.22896.

PMID:
22275341
3.

Surrogate markers and clinical indices, alone or combined, as indicators for endoscopic remission in anti-TNF-treated luminal Crohn's disease.

af Björkesten CG, Nieminen U, Turunen U, Arkkila P, Sipponen T, Färkkilä M.

Scand J Gastroenterol. 2012 May;47(5):528-37. doi: 10.3109/00365521.2012.660542.

PMID:
22356594
4.

Oxidative stress, inflammation and neutrophil superoxide release in patients with Crohn's disease: distinction between active and non-active disease.

Maor I, Rainis T, Lanir A, Lavy A.

Dig Dis Sci. 2008 Aug;53(8):2208-14. doi: 10.1007/s10620-007-0141-6.

PMID:
18253831
5.

Limitations of fecal calprotectin at diagnosis in untreated pediatric Crohn's disease.

Shaoul R, Sladek M, Turner D, Paeregaard A, Veres G, Wauters GV, Escher J, Dias JA, Lionetti P, Staino A, Kolho KL, de Ridder L, Nuti F, Cucchiara S, Sheva O, Levine A; ESPGHAN Porto IBD Group..

Inflamm Bowel Dis. 2012 Aug;18(8):1493-7. doi: 10.1002/ibd.21875.

PMID:
22275268
6.

Prediction of Crohn's disease relapse with faecal calprotectin in infliximab responders: a prospective study.

Laharie D, Mesli S, El Hajbi F, Chabrun E, Chanteloup E, Capdepont M, Razaire S, de Lédinghen V, Zerbib F.

Aliment Pharmacol Ther. 2011 Aug;34(4):462-9. doi: 10.1111/j.1365-2036.2011.04743.x.

7.
8.

Fecal calprotectin correlates more closely with the Simple Endoscopic Score for Crohn's disease (SES-CD) than CRP, blood leukocytes, and the CDAI.

Schoepfer AM, Beglinger C, Straumann A, Trummler M, Vavricka SR, Bruegger LE, Seibold F.

Am J Gastroenterol. 2010 Jan;105(1):162-9. doi: 10.1038/ajg.2009.545.

PMID:
19755969
9.

Effect of enteral nutrition on antioxidant enzyme systems and inflammation in paediatric Crohn's disease.

Phylactos AC, Fasoula IN, Arnaud-Battandier F, Walker-Smith JA, Fell JM.

Acta Paediatr. 2001 Aug;90(8):883-8.

PMID:
11529536
10.

Decreased total and corrected antioxidant capacity in patients with inflammatory bowel disease.

Koutroubakis IE, Malliaraki N, Dimoulios PD, Karmiris K, Castanas E, Kouroumalis EA.

Dig Dis Sci. 2004 Sep;49(9):1433-7.

PMID:
15481315
11.

Role of oxidative stress and antioxidant enzymes in Crohn's disease.

Iborra M, Moret I, Rausell F, Bastida G, Aguas M, Cerrillo E, Nos P, Beltrán B.

Biochem Soc Trans. 2011 Aug;39(4):1102-6. doi: 10.1042/BST0391102. Review.

PMID:
21787356
12.

Clinical utility of the assessment of fecal calprotectin in Leśniowski-Crohn's disease.

Eder P, Stawczyk-Eder K, Krela-Kaźmierczak I, Linke K.

Pol Arch Med Wewn. 2008 Nov;118(11):622-6.

13.

Mitochondrial dysfunction, persistent oxidative damage, and catalase inhibition in immune cells of naïve and treated Crohn's disease.

Beltrán B, Nos P, Dasí F, Iborra M, Bastida G, Martínez M, O'Connor JE, Sáez G, Moret I, Ponce J.

Inflamm Bowel Dis. 2010 Jan;16(1):76-86. doi: 10.1002/ibd.21027.

PMID:
19637347
14.

Cytokine tumor necrosis factor-alpha A promoter gene polymorphism at position -308 G-->A and pediatric inflammatory bowel disease: implications in ulcerative colitis and Crohn's disease.

Sýkora J, Subrt I, Dìdek P, Siala K, Schwarz J, Machalová V, Varvarovská J, Pazdiora P, Pozler O, Stozický F.

J Pediatr Gastroenterol Nutr. 2006 May;42(5):479-87.

PMID:
16707968
15.

Development and assessment of a modified Pediatric Crohn Disease Activity Index.

Leach ST, Nahidi L, Tilakaratne S, Day AS, Lemberg DA.

J Pediatr Gastroenterol Nutr. 2010 Aug;51(2):232-6. doi: 10.1097/MPG.0b013e3181d13609.

PMID:
20479686
16.

New insights into the biological and clinical significance of fecal calprotectin in inflammatory bowel disease.

Amati L, Passeri ME, Selicato F, Mastronardi ML, Penna A, Jirillo E, Covelli V.

Immunopharmacol Immunotoxicol. 2006;28(4):665-81.

PMID:
17190742
17.

[Clinical analysis of 10 cases of pediatric Crohn's disease].

Tang S, Wu XP, You JY.

Zhongguo Dang Dai Er Ke Za Zhi. 2014 Aug;16(8):824-8. Chinese.

18.

Faecal calprotectin in the assessment of Crohn's disease activity.

Gaya DR, Lyon TD, Duncan A, Neilly JB, Han S, Howell J, Liddell C, Stanley AJ, Morris AJ, Mackenzie JF.

QJM. 2005 Jun;98(6):435-41.

PMID:
15879440
19.

Correlation of MMP-3 and MMP-9 with Crohn's disease activity in children.

Kofla-Dlubacz A, Matusiewicz M, Krzystek-Korpacka M, Iwanczak B.

Dig Dis Sci. 2012 Mar;57(3):706-12. doi: 10.1007/s10620-011-1936-z.

20.

Crohn's disease: small bowel motility impairment correlates with inflammatory-related markers C-reactive protein and calprotectin.

Bickelhaupt S, Pazahr S, Chuck N, Blume I, Froehlich JM, Cattin R, Raible S, Bouquet H, Bill U, Rogler G, Frei P, Boss A, Patak MA.

Neurogastroenterol Motil. 2013 Jun;25(6):467-73. doi: 10.1111/nmo.12088.

Items per page

Supplemental Content

Support Center